# Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer

> **NCT00442260** · PHASE1,PHASE2 · COMPLETED · sponsor: **West Virginia University** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** DOXIL
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT00442260
- **Lead sponsor:** West Virginia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442260, "Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00442260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*